Key Drivers
- Strong liquidity
- Heavy R&D
- Improving Q4 cash
AIAI Summary
Moderna has pivoted into a diversified mRNA platform—settlement clarity and early oncology/combo‑vaccine wins materially de‑risk optionality—so investors should treat it as an event‑driven growth bet and specifically monitor cash runway after the $950M settlement, near‑term commercial rollout of seasonal vaccines (mNEXSPIKE/mRNA‑1010), and pivotal oncology/Phase‑3 readouts because failures or slow uptake would quickly force dilution and re‑price the premium.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Heavy R&D
- •Improving Q4 cash
MorphoSys has ample liquidity and low leverage but suffers from deep operating and free-cash-flow losses despite improved Q4 cash generation, leaving a rich valuation that prices in future optionality rather than current profitability.
Price Behavior
Key Price Behavior Insights:
- •Slightly below SMA
- •Buyers on dips
- •Elevated volatility
Trading slightly below its last month SMA (~$52.90) signals modest short-term weakness despite a sharp rebound to $57.80 that indicates buyers on dips and leaves support in the low-$50s to high-$40s (intraperiod lows ~$49.83–$49.87) amid elevated volatility between ~$49.8 and ~$57.8.
Sharp run-up to $57.80 on 2026-03-04 from late-February lows indicating heightened short-term volatility
Sentiment & News
Key News Insights:
- •Patent settlement
- •Combo vaccine momentum
- •Mixed market reaction
Moderna resolved major LNP patent disputes (clearing freedom to operate) and saw EMA momentum for its COVID‑flu combo while markets reacted generally positively but remain mindful of past revenue declines and cash burn.
The settlement and regulatory progress materially reduce legal uncertainty and improve liquidity visibility, supporting upside for the stock while near‑term performance still hinges on regulatory outcomes and cash flow
Similar Companies in Healthcare
Other companies in the same sector with AI ratings